The synthetic peptide solnatide is a novel pharmacologic agent that reduces extravascular lung water, blunts reactive oxygen species production, and improves lung function due to its ability to directly activate the epithelial sodium channel. The goal of this study was to investigate the effect of solnatide in pulmonary edema induced by acute hypobaric hypoxia and exercise in rats, which is considered a model for high-altitude pulmonary edema.
High-altitude pulmonary edema (HAPE), a lifethreatening condition, affects otherwise healthy individuals rapidly ascending to altitudes > 3,000 meters. [1] [2] [3] [4] The first detailed clinical description of HAPE can be found in a series of reports from the Mont Blanc expedition of 1891, published in Neue Zürcher Zeitung April 18 to 26, 1892. Four members of the expedition experienced HAPE, and the expedition's medical physician died of HAPE at an altitude of 4,000 meters. 5 HAPE is characterized by diffuse pulmonary edema with bloody foamy fluid present in the airways but no evidence of left ventricular failure. 6, 7 Histologic and microscopic examinations reveal hyaline membranes, arteriolar thrombi, pulmonary hemorrhages, bronchioles with inflammatory cell infiltration, infarcts, alveolar epithelial cell damage, pulmonary capillary cell connection gap widening, and thinning of the gas-blood barrier structure. 8 Early diagnosis of HAPE is essential to enable a prompt response. 9 HAPE can be avoided by acclimatization over several days. However, in emergency circumstances, acclimatization is not a feasible option. 10 Basic on-site treatment of HAPE consists of bed rest, oxygen inhalation, and IV administration of aminophylline, dexamethasone, and furosemide. 9 HAPE remains the major cause of death related to high-altitude exposure. Accordingly, there is a pressing need for an effective therapy because the number of fatalities from HAPE increases annually and because the mountain tourism industry is rapidly expanding.
11,12
The synthetic peptide, solnatide, whose molecular structure mimics the lectin-like domain of human tumor necrosis factor (TNF), 13 is a potential drug candidate to treat HAPE. Solnatide activates the lung epithelial sodium channel (ENaC), located apically in alveolar epithelial cells, by directly binding to the crucial a-subunit of the channel, thus enhancing sodium ion uptake from the alveolar space across the alveolar cell membrane. [14] [15] [16] [17] Earlier studies using rodent models of flooded lungs indicated the capacity of solnatide to improve alveolar fluid clearance. 18, 19 Solnatide reduced the extravascular lung water index and improved lung function in trauma-induced pulmonary edema in pigs, 20 as well as improved oxygenation and blunt reactive oxygen species (ROS) production in a rat lung transplantation model. 21 The safety and efficacy of orally inhaled solnatide aerosol have been reported in healthy volunteers 22 and in two interventional clinical studies of acute lung dysfunction. 23, 24 It has also been shown that the ENaC activity is decreased under hypoxic conditions in cultured rat alveolar epithelial cells and in rodent models in vivo. [25] [26] [27] The current formulation of solnatide as an aqueous aerosol allows oral inhalation into the lungs, 22 thus enabling it to rapidly reach its target and activate ENaC in the alveolar epithelium. In addition, a dry powder formulation for use with a dry powder inhaler device has been developed, allowing solnatide administration in remote areas. 28 The goal of the present study was to evaluate the capacity of solnatide to reduce edema and improve lung barrier function in an acute hypobaric hypoxia rat model for pulmonary edema, which is a type of HAPE model. 29 We assessed lung water content (LWC), protein content in BAL fluid (BALF), histology and ultra-microstructure of alveolar tissue, and expression of the tight junction protein occludin. We also evaluated the potential antiinflammatory effects of solnatide.
Materials and Methods

Animals
Adult Sprague-Dawley rats were randomly allocated to groups (30 animals per group) as shown in Table 1 . All animal experiments were conducted according to the Declaration of Helsinki conventions for the use and care of animals.
Solnatide Peptide
Solnatide peptide was provided by APEPTICO.
HAPE Model
The HAPE model was based on a previously described method. 29 Except for low-altitude control animals, all animals were exposed to acute hypobaric and hypoxic conditions in a high-altitude environment simulation chamber (DYC-2842T), highly equivalent to an altitude of 4,500 meters (at a velocity of 20 m/s within 4 min to 4,500 meters). Animals were subjected to exhaustive exercise by placing them on a treadmill at a speed of 15 m/min. After this exhaustive exercise phase, ascent to 6,000 meters was simulated and maintained until the end of the experimental schedule. After 48 h at 6,000 meters, animals were subjected to the treatment regimens shown in Table 1 over a 3-day period. Low-altitude control animals were also subjected to exhaustive exercise but were not exposed to the acute hypobaric-hypoxic condition.
Dissection and Collection of Samples
Following anesthesia with chloral hydrate, an abdominal incision was performed and blood drawn from the aorta abdominalis for analysis of cytokine levels. The chest cavity was opened and a cannula inserted into the trachea. BALF was withdrawn from the left lung after flushing it three times with sterile saline; pooled lavage fluid was centrifuged, and the supernatant was kept for determination of protein and cytokine content.
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Analytical Procedures of Relevant Indicators
Following harvesting of samples for histologic examination, the remaining right lung tissue was quickly weighed (wet weight) and dried at 60 C for 96 h to constant weight. Calculation of the LWC percentage was made according to Elliott and Jasper, 30 applying the following formula: LWC (%) ¼ (wet weight -dry weight)/wet weight Â 100%.
The protein content of BALF was determined by using the bicinchoninic assay with 96-well plates and a Synergy HT multimode microplate reader (BioTek Instruments). Cytokine detection of blood plasma and BALF was performed by using a radioimmunologic method (Zhongja Scientific Instruments) using detection kits (North Biotechnology Research Institute) for rat TNF, IL-1b, IL-6, and IL-8.
Lung Histology and Ultra-structure Analyses
Samples of right lung tissue were stored for 48 to 72 h in 4% paraformaldehyde for light microscopy or 2.5% glutaraldehyde for electron microscopy assessments. 31 Lung tissue for light microscopy analysis was paraffin-embedded, sectioned, and stained with hematoxylin and eosin. Lung tissue for electron microscopy analysis was fixed in 1% lanthanum nitrate, rinsed twice with 0.1 M dimethyl sodium arsenate buffer, and post-fixed for 2 h with 1% osmium tetroxide. After rinsing twice with 0.1 mol/L of sodium dimethyl arsenic acid, specimens were dehydrated, sliced, contrasted by using uranium acetate and lead citrate, and examined by using transmission electron microscopy.
Occludin Detection
Expression of the tight junction protein occludin was determined by using a immunohistochemical detection method with occludin polyclonal rat antibody (Abcam). 32 Occludin expression was determined by measuring the average optical density as a gray value of 10 randomly selected lung tissue slices, using the ImageJ image processing system (BI-2000 Medical Image Analysis System).
Statistical Analysis
SPSS version 19.0 software (IBM SPSS Statistics, IBM Corporation) was used for statistical analysis. Quantitative data were expressed as a percentage and measurement data as average AE SD. Comparisons between groups were performed by using single-factor analysis of variance between groups. Group means were compared by using independent sample Student t tests, with P < .05 for the difference being considered statistically significant.
Results
Lung Gross Anatomy
Lungs of animals with hypobaric hypoxia-induced pulmonary edema treated with saline were swollen, with a dark pink surface (Figs 1A and 1B), hemorrhage and abscess formation, increased hardness of tissue, and frothy exudate ( Figs 1C and 1D ). There were no macroscopic findings in the lungs of plain control animals (Figs 1E and 1F). Macroscopic examination of the lungs of animals treated with solnatide, dexamethasone, and aminophylline revealed a smooth, pale pink lung surface, without hemorrhage or abscess formation and little frothing; lungs of the solnatidetreated animals exhibited less discoloration than those of the other treatment groups.
Light Microscopy
To assess the effect of solnatide on alveolar structure in animals with hypoxia-induced pulmonary edema, a low dose (100 mg), a medium dose (300 mg), or a high dose (500 mg) was used. Light microscopy examination revealed that low-altitude control animals had normal alveolar structure, with no red blood cells or pink proteinaceous material in the alveolar space (Fig 2A) . Lung tissue from untreated animals with hypoxiainduced pulmonary edema had a compact texture, with signs of pulmonary vascular congestion, thickening of the alveolar septa, and the presence of red blood cells and pink proteinaceous material in the alveolar cavity ( Fig 2B) . Results of lung histology tests in the dexamethasone-treated animals ( Fig 2C) revealed improved alveolar structure but still some degree of alveolar septal thickening. Alveolar structure in the solnatide-treated animals at all doses tested was normal, with slight alveolar septal thickening, but there were no signs of red blood cells or proteinaceous material in the alveolar cavity (Figs 2D, 2E, 2F).
Electron Microscopy
Electron microscopy studies revealed normal lung ultrastructure in low-altitude control animals, without fusion or fractures (Fig 3A) . By contrast, profound changes to the lung ultrastructure were detected in the untreated high-altitude control animals, characterized by extensive disruption of the alveolar epithelial and capillary endothelial layers, and discontinuity of the blood-gas barrier. Disintegration of the bilayer membrane structure of capillary walls gave rise to a fuzzy or beaded appearance (Fig 3B) . Membrane bilayer structure of the alveolar epithelium, septa, and Figure 1 -A-F, Lung gross anatomy of the high-altitude control group and the low-altitude control group animals. A-B, High-altitude control group animals exhibit lung swelling and dark red discoloration. C-D, High-altitude control animals exhibit hemorrhage and abscess formation on lung surface with frothing. E-F, Low-altitude control group animals exhibit pale pink lung surface without bubble overflow.
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LWC and BALF Protein Content
As summarized in Table 1 , we evaluated the effect of the three doses of solnatide on LWC in animals with hypobaric hypoxia-and exercise-induced pulmonary edema compared with dexamethasone. Both LWC and BALF protein levels were significantly lower in all solnatide treatment groups compared with the untreated HAPE animals ( Table 2) . LWC was lowest in the medium-dose solnatide group. BALF protein was lowest in both the low-and medium-dose solnatide groups (even lower than in the low-altitude control animals). BALF protein levels in rats treated with solnatide at all dose levels were significantly lower than in rats treated with dexamethasone. 
Detection of Tight Junction Protein Occludin
Immunohistochemical staining of lung tissue (Figs 4A to 4F) found that the expression of occludin protein was strongly positive in cells of the alveolar-capillary barrier in the low-altitude control animals ( Fig 4A) and in all solnatide treatment groups ( Figs 4D, 4E, 4F ). In the untreated high-altitude animals ( Fig 4B) and dexamethasone-treated rats (Fig 4C) , the occludin expression was weakly positive.
Quantitative measurement of occludin gray scale values revealed the highest occludin expression in low-altitude control animals compared with the other groups (Table 3) , where the lowest occludin expression was observed in the untreated high-altitude control animals. Solnatide-and dexamethasone-treated animals exhibited significantly higher occludin expression than untreated high-altitude control rats. The level of occludin expression was particularly increased following treatment with Data are presented as mean AE SD. a P < .05 compared with high-altitude control animals treated with sodium chloride. b P < .01 compared with high-altitude control animals treated with sodium chloride. c P < .01 compared with high-altitude animals treated with dexamethasone. d P < .01 compared with high-altitude animals treated with aminophylline. e P < .05 compared with plain control animals not exposed to hypobaric or hypoxic conditions. f P < .01 compared with plain control animals not exposed to hypobaric or hypoxic conditions. g P < .05 compared with high-altitude animals treated with dexamethasone. h P < .05 compared with high-altitude animals treated with aminophylline. journal.publications.chestnet.org medium and high doses of solnatide and significantly higher than in dexamethasone-treated animals.
Detection of Inflammatory Cytokines
As shown in Table 4 , levels of TNF, IL-1b, IL-6, and IL-8 were significantly elevated in the blood of untreated high-altitude control animals compared with all other groups. Compared with the untreated high-altitude control animals, solnatide-treated animals had significantly lower levels of all cytokines/chemokines tested. Interestingly, TNF levels in the blood were significantly lower in animals treated with medium doses of solnatide compared with the dexamethasonetreated animals and the high-altitude control animals.
Levels of TNF, IL-1b, IL-6, and IL-8 were significantly elevated in the BALF of the untreated high-altitude control animals (Table 5) . Compared with the untreated high-altitude control animals, solnatide-treated animals had significantly lower levels of inflammatory cytokines in the BALF. Levels of TNF in the BALF of solnatide-treated animals were lower or nearly the same as those seen in low-altitude control animals and significantly lower than levels recorded for dexamethasone and untreated highaltitude control animals. Levels of IL-1b in solnatide-and dexamethasone-treated animals were significantly reduced compared with untreated high-altitude control rats. We also compared the therapeutic potency of solnatide vs aminophylline and inhibitors of mitogenactivated protein kinases and of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome (e- Tables 1-5 ).
Discussion
The dual mode of action of solnatide has been described in a battery of nonclinical studies. Upon binding of solnatide to ENaC in the airspace, the peptide increases both expression and open conformation of ENaC, thus improving sodium uptake and alveolar fluid clearance from the alveolar space across the alveolar cell membrane. Solnatide delivered by the pulmonary route was also shown to blunt ROS production upon lung transplantation and thereby improve lung function. [13] [14] [15] [16] [17] [18] [19] [20] [21] LWC is an indicator of overall lung edema severity, 33 and BALF protein is an indicator of increased alveolarcapillary membrane permeability. 34 The results of the present study showed that solnatide-treated animals experiencing acute hypobaric hypoxia and exercise had the lowest LWC of all treatment groups, significantly lower than the dexamethasone-treated animals. This finding indicates that solnatide is more efficacious for improving alveolar fluid clearance and edema resorption than the currently used agent in this model.
Solnatide was more potent in reducing the protein content in BALF than dexamethasone in this rat model. Solnatide was more effective at reducing protein leakage to the BALF and inhibiting the inflammatory cascade than current therapies for HAPE. Lower levels of IL-1b and IL-6 were found in both the BALF and blood of the solnatide-treated rats compared with the untreated animals. Significantly less TNF was detected in the BALF of solnatide-treated rats than in the dexamethasone-treated rats. Solnatide was also more potent than aminophylline in terms of LWC, BALF protein content, and inhibition of the inflammatory cascade.
Pulmonary application of solnatide resulted in increased expression of the tight junction protein occludin in alveolar walls. This finding translates into increased stability of the alveolar-capillary barrier and thus correlates with our observed reduction in the extent of protein leakage in solnatide-treated animals.
Inflammation is an important pathogenic feature of HAPE. 35 Levels of alveolar macrophages, neutrophils and lymphocytes, albumin, and low-density lipoprotein cholesterol, as well as proinflammatory cytokines and chemokines (including IL-1b, IL-6, IL-8, and TNF), are increased in the BALF of patients with HAPE. A battery of inflammatory factors is apparently involved in the pathogenesis of HAPE. Hypoxia-induced rupture of cells in the pulmonary vascular endothelium, basement membrane exposure, and release of endogenous injury material and ROS could trigger the inflammatory response. Hypoxia stress conditions and block of electron transfer of the mitochondrial respiratory chain lead to increased ROS levels. Mitochondrial complex III is the main source of ROS under hypoxic conditions. [36] [37] [38] IL-1b secretion resulting from ROS activation of the NLRP3 inflammasome is one of the major inflammatory mediators causing lung injury. 39, 40 Intratracheally applied solnatide also demonstrated potent antiinflammatory effects in a rat lung transplantation model by reducing neutrophil content and ROS generation in addition to improvement of lung function. 21 In addition, the solnatide analogue peptide AP318 significantly mitigated the pulmonary inflammation markers IL-6, TNF, Table 4 legend for expansion of other abbreviation. a P < .05 compared with high-altitude control animals treated with sodium chloride. b P < .05 compared with high-altitude animals treated with dexamethasone. c P < .01 compared with high-altitude control animals treated with sodium chloride. d P < .01 compared with high-altitude animals treated with dexamethasone. e P < .01 compared with high-altitude animals treated with aminophylline. f P < .05 compared with high-altitude animals treated with aminophylline. g P < .05 compared with plain control animals not exposed to hypobaric or hypoxic conditions. h P < .01 compared with plain control animals not exposed to hypobaric or hypoxic conditions.
journal.publications.chestnet.org cyclooxygenase-2, and tenascin C in a porcine sepsis model after pulmonary application. 41 The NLRP3 inflammasome-activated cytokine IL-1b is found at significantly increased levels in HAPE, thus implicating the NLRP3 inflammasome in its pathogenesis. Rats given NLRP3 inhibitor had significantly reduced LWC, less severe edema and local pathologic changes of the lung, improved pulmonary vascular gas-blood barrier membrane structure, and reduced leakage of proteins and cytokine content in the BALF and blood. Solnatide-treated animals showed similar effects, suggesting solnatide can inhibit and interfere with the pathway of the NLRP3 inflammasome and with cytokine activation.
Conclusions
This study showed the effectiveness of solnatide in reducing LWC and BALF protein in rats stressed by exhaustive exercise and exposed to hypoxic hypobaric conditions. In our rat model used, the results provide convincing evidence that the antiedema and antiinflammatory properties of solnatide render it more effective than currently used drugs, such as dexamethasone and aminophylline. Furthermore, solnatide exerted an inhibitory effect on proinflammatory pathways by reducing the synthesis of cytokines and the inflammatory response. In addition, solnatide increased the expression of the tight junction protein occludin, thereby improving the stability of the alveolar capillary barriers, which in turn reduced leakage of protein into the alveolar fluid. Although our model is not representative for all HAPE cases, these results nevertheless indicate a promising therapeutic potential of solnatide for the treatment of human patients with pulmonary edema exposed to a high-altitude hypoxic environment.
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